Comparison of Glycemic Excursion in Patients with New Onset Type 2 Diabetes Mellitus before and after Treatment with Repaglinide
| Autor: | Abdoljalal Marjani, Sharabeh Hezarkhani, Najmeh Shahini, Reza Rajabian, Shokufeh Bonakdaran |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Continuous glucose monitoring system business.industry medicine.medical_treatment Type 2 Diabetes Mellitus Type 2 diabetes Hypoglycemia medicine.disease Repaglinide Effective dose (pharmacology) General Biochemistry Genetics and Molecular Biology Article Diabetic diet Endocrinology Postprandial Internal medicine medicine Cardiology Glycemic excursions business Glycemic medicine.drug |
| Zdroj: | The Open Biochemistry Journal |
| ISSN: | 1874-091X |
| Popis: | Due to industrialization and sedentary life, incidence of type 2 diabetes (DM2) is increasing seriously. Repaglinide is a glucose reducing agent that predominantly reduces post-prandial glucose. Continuous glucose monitoring system (CGMS) monitors blood glucose excursions over a 3-day period. CGMS can be used as a therapeutic and diagnostic instrument in diabetics. There are not enough studies about using CGMS in DM2. The aim of this study was to determine the blood glucose excursions in patients with new onset of DM2. 10 patients with new onset of DM2 were entered to this study. As the first therapeutic management, patients received diabetic diet and moderate exercise for 3-weeks, if they did not achieve blood glucose goal (Fasting blood glucoser (FBG) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|